We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Holding AG (RHHBY) - $25 value - yours FREE >>
Pacira BioSciences, Inc. (PCRX) - $25 value - yours FREE >>
Corcept Therapeutics Incorporated (CORT) - $25 value - yours FREE >>
ANI Pharmaceuticals, Inc. (ANIP) - $25 value - yours FREE >>
Image: Bigstock
Roche Launches Accu-Chek Blood Glucose Monitoring System
Roche Holdings (RHHBY - Free Report) announced the launch of a next-generation blood glucose (BG) monitoring system, Accu-Chek Guide.
The new monitoring system will enable BG monitoring much simpler thanks to its features like the spill-resistant SmartPack test strip vial, which helps users remove just one strip at a time and avoid spillage or contamination.
Additionally, the Accu-Chek Guide system will provide high levels of accuracy, thereby facilitating better diabetes management.
The system also enables on-board pattern detection that indicated too high or too low BG readings, along with Bluetooth Low Energy connectivity to the Accu-Chek Connect diabetes management solution via a mobile app. Further, this cloud-based solution guarantees secure online data exchange and automatic data logging.
ROCHE HLDG LTD Price
ROCHE HLDG LTD Price | ROCHE HLDG LTD Quote
Roche specializes in developing drugs for oncology, immunology and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, the company focuses on innovative diagnostic solutions for the early detection and treatment of diseases. The company also leads the vitro diagnostics and tissue-based cancer diagnostics markets.
The launch of new systems will help Roche offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues. A volatile business environment in this space is expected to continue, underscoring persistent need for new diagnostic tests.
Roche currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>